A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability, and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus. - Multiple Dose Diabetes Study

Active, not recruiting

• Conditions: Type II Diabetes; MedDRA version: 9.0Level: LLTClassification code 10045242

• Registration Number: EUCTR2005-003869-17-DE
• Lead Sponsor: Merck & Co., Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-07-06
• Last Update Posted: 27 January 2014

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

Patient is a male or female (non-childbearing potential) between the ages of 21 and 65 years with type 2 diabetes and whose weight is a Body Mass Index (BMI) that is from 20 to 40 kg/m2.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Subject has clinically significant abnormalities in the physical examination or laboratory safety tests, history of cardiovascular disease, renal disease, type 1 diabetes, hepatic disease, and neoplastic disease or in the opinion of the investigator has any condition which may compromise safety or the clear interpretation of data from the trial.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified